Press release
Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR)
A lawsuit was filed on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) shares over alleged securities laws violations.
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Francisco, CA based Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. Shares of Nektar Therapeutics (NASDAQ: NKTR) grew from $11.94 per share in early 2017 to as high as $109.32 per share on March 2018.
On August 8, 2019, after-market hours, Nektar Therapeutics announced that a manufacturing issue caused two out of the twenty batches of bempegaldesleukin to differ from the production line. These faulty batches resulted in variable clinical benefit than other batches used in its PIVOT-02 clinical trial.
Shares of Nektar Therapeutics (NASDAQ: NKTR) declined to as low as $17.30 per share on August 14, 2019.
The plaintiff claims that between February 15, 2019 and August 8, 2019, the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) here
News-ID: 1826777 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Nektar
Mead Beverages Market Is Booming So Rapidly | Medovina, Nektar, Kuhnhenn
The "Mead Beverages Market" intelligence report, just published by USD Analytics, covers a micro-level study of important market niches, product offers, and sales channels. To determine market size, potential, growth trends, and competitive environment, the Mead Beverages Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured Redstone…
Mead Beverages Market to Eyewitness Massive Growth by 2030 | Redstone, Nektar, M …
Latest Study on Industrial Growth of Global Mead Beverages Market 2022-2028. A detailed study accumulated to offer Latest insights about acute features of the Mead Beverages Market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and…
Targeted Therapeutics Market Future Outlook 2022-2028 | Pfizer, Nektar Therapeut …
Targeted therapy is a type of cancer treatment that targets proteins that control the way cancer cells grow, divide, and spread. It is the basis of precision medicine.
Rising cancer prevalence and disposable income of people are expected to increase demand for the product. The widespread prevalence of cancer is a major driver for the targeted therapeutics market. Due to the surge in smoking, the number of people affected by it…
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.
Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over…
Inhalers Market SWOT Analysis | Acorda Therapeutics, Adamis Pharmaceuticals, Ara …
HTF Market Intelligence released a new research report of 357 pages on title 'Inhalers - Medical Devices Pipeline Assessment, 2019' with detailed analysis, forecast and strategies. The study covers key regions and important players such as Acorda Therapeutics Inc, Adamis Pharmaceuticals Corp, Advent Pharmaceuticals Pty Ltd, Aespira Ltd., AKELA Pharma Inc., Alexza Pharmaceuticals Inc, Aradigm Corp, AstraZeneca Plc, Bayer AG, Bellerophon Therapeutics Inc, Bespak Europe Ltd, Boehringer Ingelheim GmbH,…
Mead Beverages Global Market 2018: Key Players – Redstone, Brothers Drake, Med …
Mead Beverages Industry
Description
Wiseguyreports.Com Adds “Mead Beverages -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database
The global Mead Beverages market will reach Million USD in 2017 and CAGR xx% 2011-2017. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Mead Beverages by product, region and application, in addition, this report introduces market…
